cancer drug glutathione Glutathione-responsive biodegradable polyurethane nanoparticles for lung treatment Human cancer-associated fibroblasts enhance glutathione

A narrative review of glutathione supplementation reported that 37.5 percent of participants receiving 1.2 g of glutathione twice weekly for six weeks experienced temporary lightening, yet benefits faded within six months, and 32 percent experienced adverse events such as liver dysfunction or anaphylaxis

Studies have demonstrated that curcumin undergoes extensive glucuronidation rapidly after oral administration, leading to extremely low plasma concentrations of the parent drug (often below 1%) ( The substantial disparity between in vivo and ex vivo concentrations suggests that mechanistic conclusions derived solely from ex vivo cellular experiments, which typically involve direct exposure to high concentrations of the parent drug, may not be directly extrapolated to the in vivo context

2016;11(12): e0169159

In addition, cholesterol is thought to contribute to the lipid peroxidation burden during ferroptosis [100]